---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-199157"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:15:41.236476+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "low"
source: SEC EDGAR
---

# Aldeyra provides reproxalap trial endpoint estimates and FDA stance in corporate overview

## Summary
- Standardized treatment estimates and confidence intervals disclosed for reproxalap dry eye disease clinical trials primary endpoints.
- Aldeyra summarizes its interpretations of FDA positions on primary endpoints and its own positions in the NDA.
- Presentation is a voluntary Reg FD disclosure; no financial results or guidance included.

## SEC filing metadata
- accession: 0001193125-26-199157
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000119312526199157/0001193125-26-199157-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000119312526199157/aldx-20260501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-199157
- JSON: https://secwatch.observer/filing/0001193125-26-199157.json
- Plain text: https://secwatch.observer/filing/0001193125-26-199157.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.